or Try an Advanced Search...

    Technical Analysis for CVAC - CureVac N.V.

    Grade Last Price % Change Price Change
    F 3.33 -2.06% -0.07
    CVAC closed down 2.06 percent on Monday, July 1, 2024, on 56 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CVAC trend table...
    Date Alert Name Type % Chg
    Fell Below 50 DMA Bearish 0.00%
    180 Bearish Setup Bearish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Stochastic Buy Signal Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    50 DMA Support Bullish -2.06%
    NR7 Range Contraction -2.06%
    Narrow Range Bar Range Contraction -2.06%
    Wide Bands Range Expansion -2.06%
    Older End-of-Day Signals for CVAC ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 7 hours ago
    Down 1% about 7 hours ago
    Fell Below 50 DMA about 7 hours ago
    10 DMA Support about 9 hours ago
    50 DMA Support about 9 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    CVAC Chart by TradingView
    Basic chart:

    Profile

    CureVac N.V. Description

    CureVac B.V., a clinical-stage biopharmaceutical company, engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102 that is in a Phase I clinical trial for the treatment of various types of solid tumors; and CV7202, which is investigating in a Phase I clinical trial for vaccination against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase I clinical trial. The company has collaboration and license agreements with GlaxoSmithKline Biologicals SA, Genmab B.V., Boehringer Ingelheim GmbH, and Eli Lilly and Company; development and option agreements with Arcturus Therapeutics, Inc., Acuitas Therapeutics Inc., and CRISPR Therapeutics AG; and a development and intellectual property agreement with Tesla Grohmann Automation GmbH. CureVac B.V. was founded in 2000 and is headquartered in Tübingen, Germany.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Pharmaceutical Solid Tumors Acid Health Care Coronavirus Vaccination CRISPR Rabies Arcturus Therapeutics Genmab

    Is CVAC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 24 CureVac Announces Voting Results of General Meeting
    Jun 6 First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map
    May 30 Third human bird flu case found in U.S.
    May 28 CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
    May 26 CureVac N.V. (NASDAQ:CVAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
    May 25 CureVac First Quarter 2024 Earnings: Misses Expectations
    May 23 CureVac: Remains A Hold Based On Bird Flu Vaccine And Oncology Advancements
    May 23 Heard on the Street: Moderna Got a Boost From Bird Flu, but Don’t Count Your Chicks
    May 23 Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
    May 23 CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
    See more CVAC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 10.77
    52 Week Low 2.215
    Average Volume 1,260,673
    200-Day Moving Average 4.27
    50-Day Moving Average 3.39
    20-Day Moving Average 3.84
    10-Day Moving Average 3.37
    Average True Range 0.33
    RSI (14) 43.50
    ADX 21.77
    +DI 25.40
    -DI 22.58
    Chandelier Exit (Long, 3 ATRs) 4.30
    Chandelier Exit (Short, 3 ATRs) 4.11
    Upper Bollinger Bands 4.90
    Lower Bollinger Band 2.77
    Percent B (%b) 0.26
    BandWidth 55.54
    MACD Line -0.08
    MACD Signal Line 0.01
    MACD Histogram -0.0845
    Fundamentals Value
    Market Cap 745.67 Million
    Num Shares 224 Million
    EPS -1.58
    Price-to-Earnings (P/E) Ratio -2.11
    Price-to-Sales 18.27
    Price-to-Book 1.18
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.69
    Resistance 3 (R3) 3.73 3.65 3.63
    Resistance 2 (R2) 3.65 3.56 3.63 3.61
    Resistance 1 (R1) 3.49 3.50 3.45 3.45 3.59
    Pivot Point 3.41 3.41 3.39 3.39 3.41
    Support 1 (S1) 3.25 3.32 3.21 3.21 3.07
    Support 2 (S2) 3.17 3.26 3.15 3.05
    Support 3 (S3) 3.01 3.17 3.03
    Support 4 (S4) 2.97